Pesticides & Agrochemicals · Founded 1989 · www.bharatgroup.co.in · BSE 590021 · NSE BHARATRAS · ISIN INE838B01021
No Notes Added Yet
Business
Bharat Rasayan Ltd. is an Indian company primarily engaged in the manufacturing and marketing of technical-grade pesticides, intermediates, and pesticide formulations. The company's core business model involves developing and producing a diverse range of agrochemicals that protect crops from pests, weeds, and diseases. It caters to both the domestic and international markets, supplying its products to other agrochemical formulators and distributors. The company makes money by selling these essential crop protection chemicals.
Revenue Mix
Bharat Rasayan's revenue primarily stems from its agrochemical business, which can typically be broken down into:
Technical Grade Products: Manufacturing active ingredients (technical products) that are then used by other companies to create their own formulations. This is often a B2B segment.
Formulations: Producing ready-to-use pesticide formulations (e.g., insecticides, herbicides, fungicides) that are directly sold to farmers or distributors.
Intermediates: Manufacturing chemical intermediates that are used in the synthesis of the final technical-grade products.
While specific revenue contributions for these segments are not readily available without detailed financial reports, the company is known for its strong focus on technical-grade manufacturing.
Industry
The Pesticides & Agrochemicals industry in India is characterized by its reliance on the agricultural sector's performance, monsoon patterns, and government policies. It's a competitive market with a mix of large multinational corporations, prominent domestic players (e.g., UPL, PI Industries, Rallis India), and numerous smaller regional companies. Bharat Rasayan Ltd. positions itself as an established Indian manufacturer with capabilities in synthesizing complex molecules. Its strength likely lies in its manufacturing expertise and process chemistry for various technical products, allowing it to compete effectively both domestically and in export markets for off-patent agrochemicals.
MOAT
Bharat Rasayan's competitive advantages likely include:
Process Chemistry Expertise: Ability to efficiently synthesize a range of complex technical-grade active ingredients, offering cost-effective production.
Manufacturing Scale & Integration: Established manufacturing facilities and backward integration for key intermediates can provide cost efficiencies and supply chain reliability.
Regulatory Approvals & Registrations: Securing necessary regulatory approvals for its products in various domestic and international markets creates a barrier to entry for new competitors.
Customer Relationships: Long-standing relationships with B2B clients (other formulators) built on product quality and reliable supply.
Growth Drivers
Key factors that can drive Bharat Rasayan's growth over the next 3-5 years include:
Growth in Agricultural Output: Increasing demand for food globally and in India drives the need for crop protection.
New Product Development & Registrations: Introduction of new technicals and formulations, especially those with better efficacy or environmental profiles.
Capacity Expansions: Investing in new manufacturing capacities to meet growing domestic and export demand.
Export Opportunities: Leveraging its manufacturing capabilities to tap into global markets, particularly for generic off-patent molecules.
Increasing Farmer Awareness: Greater adoption of modern farming practices and crop protection solutions by Indian farmers.
Risks
Key business risks for Bharat Rasayan Ltd. include:
Monsoon Dependency: Indian agriculture is heavily reliant on monsoon, impacting farmer income and demand for agrochemicals.
Raw Material Price Volatility: Fluctuations in the prices of key chemical inputs can impact manufacturing costs and profitability.
Regulatory Changes: Stricter environmental regulations, potential bans on certain molecules, or changes in registration processes could impact operations.
Intense Competition: The industry is competitive, leading to pricing pressures and potential loss of market share.
Counterfeit Products: The presence of spurious agrochemicals in the market can erode sales and brand reputation.
Environmental Concerns: Growing global scrutiny over pesticide use could lead to restrictions or demand shifts.
Management & Ownership
Bharat Rasayan Ltd. is a promoter-driven company, typical of many Indian businesses. The promoter group holds a significant stake, indicating a strong commitment to the company's long-term vision. Management generally comprises experienced professionals with a deep understanding of the chemical and agrochemical industries, guiding the company's manufacturing, R&D, and market expansion strategies.
Outlook
Bharat Rasayan is well-positioned within the essential agrochemical sector, benefiting from the underlying demand for food security and increasing agricultural productivity. The company's established manufacturing base and technical expertise provide a solid foundation. Potential tailwinds include growing global agricultural demand, increasing farmer awareness in India, and opportunities in export markets. However, the business remains susceptible to the vagaries of monsoon, volatile raw material prices, and evolving regulatory landscapes, both domestically and internationally. Competition is also a constant factor. While new product development and capacity expansion offer avenues for growth, these must be balanced against execution risks and market acceptance.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 310 | 282 | 328 | 256 | 307 | 377 | 286 | 270 | 308 | 338 |
| Other Income | 11 | 6 | 7 | 7 | 6 | 7 | 9 | 9 | 16 | 6 |
| Total Income | 321 | 288 | 335 | 264 | 313 | 385 | 295 | 280 | 324 | 344 |
| Total Expenditure | 240 | 244 | 273 | 215 | 266 | 304 | 253 | 228 | 258 | 287 |
| Operating Profit | 80 | 44 | 62 | 49 | 46 | 80 | 42 | 52 | 66 | 56 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 6 | 6 | 7 | 7 | 7 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -15 | 0 | 1 | -6 | 0 |
| Profit Before Tax | 73 | 37 | 54 | 41 | 38 | 58 | 35 | 46 | 52 | 48 |
| Provision for Tax | 17 | 10 | 14 | 11 | 9 | 14 | 8 | 12 | 13 | 12 |
| Profit After Tax | 56 | 27 | 40 | 30 | 28 | 44 | 26 | 34 | 39 | 37 |
| Adjustments | 11 | 16 | -8 | 11 | -3 | -4 | 2 | 6 | -1 | 1 |
| Profit After Adjustments | 67 | 43 | 32 | 41 | 25 | 40 | 28 | 40 | 38 | 37 |
| Adjusted Earnings Per Share | 40.4 | 25.9 | 19.3 | 24.4 | 15.1 | 23.9 | 16.8 | 24.1 | 23 | 22.4 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 992 | 1215 | 1092 | 1301 | 1234 | 1045 | 1173 | 1242 | 1202 |
| Other Income | 3 | 17 | 7 | 16 | 19 | 21 | 26 | 41 | 40 |
| Total Income | 995 | 1232 | 1099 | 1317 | 1254 | 1066 | 1199 | 1283 | 1243 |
| Total Expenditure | 805 | 985 | 852 | 1049 | 1037 | 927 | 998 | 1043 | 1026 |
| Operating Profit | 190 | 247 | 247 | 267 | 217 | 139 | 201 | 241 | 216 |
| Interest | 16 | 16 | 4 | 7 | 6 | 3 | 5 | 5 | 4 |
| Depreciation | 17 | 22 | 26 | 25 | 26 | 26 | 27 | 26 | 27 |
| Exceptional Income / Expenses | -2 | -3 | -1 | -0 | -4 | 0 | 0 | -19 | -5 |
| Profit Before Tax | 155 | 205 | 215 | 234 | 174 | 123 | 185 | 193 | 181 |
| Provision for Tax | 44 | 48 | 51 | 58 | 49 | 28 | 44 | 48 | 45 |
| Profit After Tax | 112 | 158 | 164 | 176 | 125 | 96 | 141 | 146 | 136 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Profit After Adjustments | 112 | 158 | 164 | 176 | 125 | 96 | 141 | 146 | 143 |
| Adjusted Earnings Per Share | 65.6 | 92.8 | 96.4 | 105.9 | 75 | 57.5 | 84.8 | 87.7 | 86.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 6% | 0% | 3% | 0% |
| Operating Profit CAGR | 20% | 4% | -0% | 0% |
| PAT CAGR | 4% | 5% | -2% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -61% | -24% | -19% | 8% |
| ROE Average | 12% | 12% | 15% | 20% |
| ROCE Average | 16% | 15% | 18% | 23% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 409 | 564 | 727 | 770 | 893 | 988 | 1130 | 1275 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 40 | 22 | 0 | 1 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14 | 12 | 10 | 10 | 10 | 13 | 17 | 21 |
| Total Current Liabilities | 293 | 153 | 170 | 309 | 173 | 197 | 262 | 137 |
| Total Liabilities | 756 | 752 | 908 | 1090 | 1076 | 1198 | 1409 | 1433 |
| Fixed Assets | 150 | 203 | 191 | 228 | 225 | 230 | 230 | 246 |
| Other Non-Current Assets | 42 | 30 | 67 | 61 | 58 | 60 | 86 | 126 |
| Total Current Assets | 564 | 519 | 650 | 801 | 793 | 907 | 1094 | 1061 |
| Total Assets | 756 | 752 | 908 | 1090 | 1076 | 1198 | 1409 | 1433 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 6 | 46 | 27 | 0 | 19 | 32 | 55 |
| Cash Flow from Operating Activities | -52 | 263 | 170 | -65 | 213 | 41 | 172 | 132 |
| Cash Flow from Investing Activities | -48 | -68 | -153 | 51 | -61 | -90 | -157 | -96 |
| Cash Flow from Financing Activities | 102 | -169 | -40 | -25 | -152 | 49 | -1 | -89 |
| Net Cash Inflow / Outflow | 3 | 25 | -22 | -39 | 1 | 0 | 14 | -53 |
| Closing Cash & Cash Equivalent | 6 | 46 | 27 | 0 | 19 | 32 | 55 | 23 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 65.62 | 92.76 | 96.43 | 105.88 | 74.97 | 57.47 | 84.79 | 87.68 |
| CEPS(Rs) | 75.56 | 105.67 | 111.58 | 120.89 | 90.63 | 72.98 | 101.03 | 103.54 |
| DPS(Rs) | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 | 0.5 |
| Book NAV/Share(Rs) | 240.55 | 331.94 | 427.95 | 463.29 | 537.46 | 594.37 | 679.87 | 766.95 |
| Core EBITDA Margin(%) | 18.9 | 18.93 | 22 | 19.33 | 15.99 | 11.27 | 14.92 | 16.05 |
| EBIT Margin(%) | 17.28 | 18.24 | 20.13 | 18.52 | 14.59 | 12.13 | 16.19 | 15.95 |
| Pre Tax Margin(%) | 15.64 | 16.89 | 19.72 | 17.96 | 14.1 | 11.8 | 15.77 | 15.57 |
| PAT Margin (%) | 11.24 | 12.97 | 15.01 | 13.53 | 10.1 | 9.14 | 12.01 | 11.73 |
| Cash Profit Margin (%) | 12.94 | 14.78 | 17.37 | 15.44 | 12.2 | 11.61 | 14.31 | 13.86 |
| ROA(%) | 14.76 | 20.91 | 19.75 | 17.62 | 11.51 | 8.4 | 10.81 | 10.26 |
| ROE(%) | 27.28 | 32.41 | 25.38 | 23.51 | 14.98 | 10.15 | 13.31 | 12.12 |
| ROCE(%) | 26.14 | 33.74 | 30.45 | 27.87 | 19.31 | 12.74 | 16.63 | 15.91 |
| Receivable days | 102.67 | 79.56 | 91.28 | 106.5 | 116.62 | 125.56 | 126.47 | 118.25 |
| Inventory Days | 77.34 | 55.66 | 54.96 | 62.52 | 88.76 | 103.03 | 86.66 | 91.25 |
| Payable days | 23.79 | 18.23 | 26.8 | 28.02 | 31.1 | 37.37 | 50.49 | 54.1 |
| PER(x) | 15.93 | 14.04 | 24.39 | 28.76 | 30.32 | 36.97 | 31.06 | 13.79 |
| Price/Book(x) | 4.35 | 3.92 | 5.49 | 6.57 | 4.23 | 3.57 | 3.87 | 1.58 |
| Dividend Yield(%) | 0.04 | 0.03 | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | 0.04 |
| EV/Net Sales(x) | 2.03 | 1.86 | 3.68 | 4.02 | 3.06 | 3.41 | 3.76 | 1.6 |
| EV/Core EBITDA(x) | 10.6 | 9.14 | 16.26 | 19.57 | 17.41 | 25.71 | 21.92 | 8.27 |
| Net Sales Growth(%) | 0 | 22.46 | -10.13 | 19.14 | -5.12 | -15.37 | 12.29 | 5.87 |
| EBIT Growth(%) | 0 | 29.27 | -0.84 | 9.67 | -25.28 | -29.65 | 49.89 | 4.33 |
| PAT Growth(%) | 0 | 41.35 | 3.95 | 7.39 | -29.19 | -23.35 | 47.54 | 3.41 |
| EPS Growth(%) | 0 | 41.35 | 3.95 | 9.81 | -29.19 | -23.35 | 47.54 | 3.41 |
| Debt/Equity(x) | 0.6 | 0.17 | 0.08 | 0.23 | 0.03 | 0.08 | 0.08 | 0 |
| Current Ratio(x) | 1.92 | 3.38 | 3.82 | 2.6 | 4.6 | 4.6 | 4.18 | 7.77 |
| Quick Ratio(x) | 1.21 | 2.33 | 2.83 | 1.7 | 2.72 | 3.25 | 3.07 | 5.35 |
| Interest Cover(x) | 10.51 | 13.48 | 49.78 | 32.82 | 29.56 | 37.49 | 38.78 | 41.66 |
| Total Debt/Mcap(x) | 0.14 | 0.04 | 0.01 | 0.03 | 0.01 | 0.02 | 0.02 | 0 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 |
| FII | 0.35 | 0.46 | 0.45 | 0.49 | 0.56 | 0.47 | 0.43 | 0.54 | 0.41 | 0.58 |
| DII | 2.59 | 2.64 | 2.6 | 2.75 | 2.74 | 2.75 | 2.52 | 2.14 | 2 | 1.7 |
| Public | 22.07 | 21.9 | 21.96 | 21.77 | 21.71 | 21.79 | 22.05 | 22.33 | 22.61 | 22.72 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 1.25 | 1.25 | 1.25 | 1.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.03 | 0.03 |
| Public | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.37 | 0.37 | 0.38 | 0.38 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 1.66 | 1.66 | 1.66 | 1.66 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +6% | 0% | +3% | — |
| Operating Profit CAGR | +20% | +4% | 0% | — |
| PAT CAGR | +4% | +5% | -2% | — |
| Share Price CAGR | -61% | -24% | -19% | +8% |
| ROE Average | +12% | +12% | +15% | +20% |
| ROCE Average | +16% | +15% | +18% | +23% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 |
| FII | 0.35 | 0.46 | 0.45 | 0.49 | 0.56 | 0.47 | 0.43 | 0.54 | 0.41 | 0.58 |
| DII | 2.59 | 2.64 | 2.6 | 2.75 | 2.74 | 2.75 | 2.52 | 2.14 | 2 | 1.7 |
| Public | 22.07 | 21.9 | 21.96 | 21.77 | 21.71 | 21.79 | 22.05 | 22.33 | 22.61 | 22.72 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 1.25 | 1.25 | 1.25 | 1.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.03 | 0.03 |
| Public | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.37 | 0.37 | 0.38 | 0.38 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 1.66 | 1.66 | 1.66 | 1.66 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.